J

Jazz Pharmaceuticals plc
D

JAZZ

136.050
USD
-0.64
(-0.47%)
مغلق
حجم التداول
25,640
الربح لكل سهم
20
العائد الربحي
-
P/E
19
حجم السوق
8,224,847,242
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    AZN
    AZN
    -0.350
    (-0.47%)
    74.220 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    LLY
    LLY
    0.67
    (0.08%)
    874.04 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    NVS
    NVS
    2.100
    (1.96%)
    109.370 USD
    PFE
    PFE
    0.405
    (1.56%)
    26.305 USD
    SNY
    SNY
    0.325
    (0.60%)
    54.445 USD
    المزيد
الأخبار
المقالات

العنوان: Jazz Pharmaceuticals plc

القطاع: Healthcare
الصناعة: Biotechnology
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.